| | |
Price to
Public(1) |
| |
Underwriting
Discount |
| |
Proceeds Before
Expenses to Issuer(1) |
| |||||||||
Per Note
|
| | | | % | | | | | | % | | | | | | % | | |
Total
|
| | | $ | | | | | $ | | | | | $ | | |
| Credit Suisse | | |
J.P. Morgan
|
| |
Citigroup
|
|
|
Barclays
|
| |
TD Securities
|
|
|
HSBC
|
| |
Mizuho Securities
|
| |
RBC Capital Markets
|
|
| | | | | S-1 | | | |
| | | | | S-2 | | | |
| | | | | S-4 | | | |
| | | | | S-6 | | | |
| | | | | S-9 | | | |
| | | | | S-13 | | | |
| | | | | S-27 | | | |
| | | | | S-28 | | | |
| | | | | S-29 | | | |
| | | | | S-30 | | | |
| | | | | S-51 | | | |
| | | | | S-55 | | | |
| | | | | S-55 | | | |
| | | | | S-55 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 5 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 27 | | | |
| | | | | 30 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| | | | | 40 | | | |
| | | | | 43 | | | |
| | | | | 63 | | | |
| | | | | 65 | | | |
| | | | | 68 | | | |
| | | | | 69 | | | |
| | | | | 71 | | | |
| | | | | 71 | | |
| | |
Three Months
Ended March 31, |
| |
Year Ended
December 31, |
| ||||||||||||||||||
(In millions)
|
| |
2017
|
| |
2016
|
| |
2016
|
| |
2015
|
| ||||||||||||
Statement of Operations | | | | | | ||||||||||||||||||||
Net sales
|
| | | $ | 1,437 | | | | | $ | 1,297 | | | | | $ | 5,400 | | | | | $ | 5,717 | | |
Cost of goods sold
|
| | | | 1,079 | | | | | | 1,095 | | | | | | 4,290 | | | | | | 4,762 | | |
Selling, general and administrative expense
|
| | | | 144 | | | | | | 133 | | | | | | 934 | | | | | | 632 | | |
Research and development expense
|
| | | | 19 | | | | | | 23 | | | | | | 80 | | | | | | 97 | | |
Employee separation and asset related charges, net
|
| | | | 12 | | | | | | 17 | | | | | | 170 | | | | | | 333 | | |
Goodwill impairment
|
| | | | — | | | | | | — | | | | | | — | | | | | | 25 | | |
Total expenses
|
| | | | 175 | | | | | | 173 | | | | | | 1,184 | | | | | | 1,087 | | |
Equity in earnings of affiliates
|
| | | | 7 | | | | | | 5 | | | | | | 29 | | | | | | 22 | | |
Interest expense, net
|
| | | | (51) | | | | | | (57) | | | | | | (213) | | | | | | (132) | | |
Other income, net
|
| | | | 34 | | | | | | 93 | | | | | | 247 | | | | | | 54 | | |
Income (Loss) before income taxes
|
| | | | 173 | | | | | | 70 | | | | | | (11) | | | | | | (188) | | |
Provision for (benefit from) income taxes
|
| | | | 22 | | | | | | 19 | | | | | | (18) | | | | | | (98) | | |
Net income (loss)
|
| | | | 151 | | | | | | 51 | | | | | | 7 | | | | | | (90) | | |
Less: Net income attributable to noncontrolling interests
|
| | | | 1 | | | | | | — | | | | | | — | | | | | | — | | |
Net income (loss) attributable to Chemours
|
| | | | 150 | | | | | | 51 | | | | | | 7 | | | | | | (90) | | |
Statement of Cash Flows: | | | | | | ||||||||||||||||||||
Operating activities:
|
| | | | 41 | | | | | | 36 | | | | | | 594 | | | | | | 182 | | |
Investing activities:
|
| | | | (63) | | | | | | 50 | | | | | | 357 | | | | | | (497) | | |
Financing activities:
|
| | | | 11 | | | | | | (16) | | | | | | (396) | | | | | | 687 | | |
| | |
As of March 31,
|
| |
As of December 31,
|
| ||||||||||||||||||
(In millions)
|
| |
2017
|
| |
2016
|
| |
2016
|
| |
2015
|
| ||||||||||||
Financial position at end of period: | | | | | | ||||||||||||||||||||
Working capital(a)
|
| | | | 976 | | | | | | 884 | | | | | | 782 | | | | | | 835 | | |
Total assets
|
| | | | 6,282 | | | | | | 6,380 | | | | | | 6,060 | | | | | | 6,298 | | |
Borrowings and capital lease obligations, net(b)
|
| | | | 3,552 | | | | | | 3,954 | | | | | | 3,544 | | | | | | 3,954 | | |
| | |
Three Months
Ended March 31, |
| |
Year Ended
December 31, |
| ||||||||||||||||||
| | |
2017
|
| |
2016
|
| |
2016
|
| |
2015
|
| ||||||||||||
Other Financial Data | | | | | | ||||||||||||||||||||
Adjusted EBITDA(a)
|
| | | | 285 | | | | | | 128 | | | | | | 822 | | | | | | 573 | | |
Adjusted Net Income(a)
|
| | | | 142 | | | | | | 11 | | | | | | 187 | | | | | | 143 | | |
Free Cash Flow(a)
|
| | | | (28) | | | | | | (53) | | | | | | 256 | | | | | | (337) | | |
Purchases of property, plant and equipment
|
| | | | (69) | | | | | | (89) | | | | | | 338 | | | | | | 519 | | |
Depreciation and amortization
|
| | | | 71 | | | | | | 66 | | | | | | 284 | | | | | | 267 | | |
Segment Data | | | | | | ||||||||||||||||||||
Titanium Technologies: | | | | | | ||||||||||||||||||||
Segment Net Sales
|
| | | | 646 | | | | | | 521 | | | | | | 2,364 | | | | | | 2,392 | | |
Adjusted EBITDA
|
| | | | 159 | | | | | | 54 | | | | | | 466 | | | | | | 326 | | |
Adjusted EBITDA Margin(b)
|
| | | | 25% | | | | | | 10% | | | | | | 20% | | | | | | 14% | | |
Fluoroproducts: | | | | | | ||||||||||||||||||||
Segment Net Sales
|
| | | | 652 | | | | | | 531 | | | | | | 2,264 | | | | | | 2,230 | | |
Adjusted EBITDA
|
| | | | 155 | | | | | | 85 | | | | | | 445 | | | | | | 300 | | |
Adjusted EBITDA Margin
|
| | | | 24% | | | | | | 16% | | | | | | 20% | | | | | | 13% | | |
Chemical Solutions: | | | | | | ||||||||||||||||||||
Segment Net Sales
|
| | | | 139 | | | | | | 245 | | | | | | 772 | | | | | | 1,095 | | |
Adjusted EBITDA
|
| | | | 12 | | | | | | 10 | | | | | | 39 | | | | | | 29 | | |
Adjusted EBITDA Margin
|
| | | | 9% | | | | | | 4% | | | | | | 5% | | | | | | 3% | | |
| | |
Three Months
Ended March 31, |
| |
Year Ended
December 31, |
| |
Last
Twelve Months (LTM)(e) |
| |||||||||||||||||||||
(In millions)
|
| |
2017
|
| |
2016
|
| |
2016
|
| |
2015
|
| ||||||||||||||||||
Reconciliation of GAAP Net Income Attributable to Chemours to Adjusted EBITDA
|
| | | | | | |||||||||||||||||||||||||
Net income (loss) attributable to Chemours
|
| | | | 150 | | | | | | 51 | | | | | | 7 | | | | | | (90) | | | | | $ | 106 | | |
Non-operating pension and other postretirement employee benefit
income |
| | | | (8) | | | | | | (7) | | | | | | (20) | | | | | | (3) | | | | | | (21) | | |
Exchange (gains) losses
|
| | | | (5) | | | | | | 6 | | | | | | 57 | | | | | | (19) | | | | | | 46 | | |
Restructuring charges
|
| | | | 12 | | | | | | 17 | | | | | | 51 | | | | | | 285 | | | | | | 46 | | |
Asset related charges(a)
|
| | | | — | | | | | | — | | | | | | 124 | | | | | | 73 | | | | | | 123 | | |
(Gain) loss on sale of assets or business
|
| | | | (16) | | | | | | (89) | | | | | | (254) | | | | | | 9 | | | | | | (181) | | |
Transaction costs(b)
|
| | | | — | | | | | | 3 | | | | | | 19 | | | | | | 9 | | | | | | 15 | | |
Legal and other charges(c)
|
| | | | 7 | | | | | | 5 | | | | | | 359 | | | | | | 8 | | | | | | 361 | | |
Provision for (benefit from) income taxes relating to reconciling items(d)
|
| | | | 2 | | | | | | 25 | | | | | | (156) | | | | | | (129) | | | | | | (177) | | |
Adjusted Net Income
|
| | | | 142 | | | | | | 11 | | | | | | 187 | | | | | | 143 | | | | | $ | 318 | | |
Net income attributable to noncontrolling interests
|
| | | | 1 | | | | | | — | | | | | | — | | | | | | — | | | | | | 1 | | |
Interest expense, net
|
| | | | 51 | | | | | | 57 | | | | | | 213 | | | | | | 132 | | | | | | 208 | | |
Depreciation and amortization
|
| | | | 71 | | | | | | 66 | | | | | | 284 | | | | | | 267 | | | | | | 289 | | |
All remaining provision for (benefit from) income taxes(d)
|
| | | | 20 | | | | | | (6) | | | | | | 138 | | | | | | 31 | | | | | | 163 | | |
Adjusted EBITDA
|
| | | | 285 | | | | | | 128 | | | | | | 822 | | | | | | 573 | | | | | $ | 979 | | |
|
| | |
Three Months
Ended March 31, |
| |
Year Ended
December 31, |
| ||||||||||||||||||
(In millions)
|
| |
2017
|
| |
2016
|
| |
2016
|
| |
2015
|
| ||||||||||||
Reconciliation of GAAP Cash Flow to Free Cash Flow | | | | | | ||||||||||||||||||||
Cash flow provided by operating activities
|
| | | | 41 | | | | | | 36(1) | | | | | | 594 | | | | | | 182 | | |
Cash flow used for purchases of property, plant and equipment
|
| | | | (69) | | | | | | (89) | | | | | | (338) | | | | | | (519) | | |
Free Cash Flow
|
| | | | (28) | | | | | | (53) | | | | | | 256 | | | | | | (337) | | |
|
| | |
March 31, 2017
|
| |||||||||
| | |
Actual
|
| |
As adjusted
for this offering |
| ||||||
| | |
(unaudited in 000’s)
|
| |||||||||
Cash and Cash Equivalents
|
| | | $ | 898 | | | | | $ | 1,392(4) | | |
Long-term debt, including current portion:(1) | | | | | | | | | | | | | |
Senior secured term loan(2)
|
| | | | 1,369 | | | | | | 1,369 | | |
Senior unsecured notes
|
| | | | | | | | | | | | |
6.625% due May 2023
|
| | | | 1,158 | | | | | | 1,158 | | |
7.00% due May 2025
|
| | | | 750 | | | | | | 750 | | |
6.125% due May 2023 (€295 at March 31, 2017)(3)
|
| | | | 318 | | | | | | 318 | | |
% senior notes due 2027, offered hereby
|
| | | | | | | | | | 500 | | |
Capital lease obligations
|
| | | | 3 | | | | | | 3 | | |
Total debt
|
| | |
|
3,598
|
| | | |
|
4,098
|
| |
Equity: | | | | | | | | | | | | | |
Common stock (par value $0.01 per share)
|
| | | | 2 | | | | | | 2 | | |
Additional paid-in capital
|
| | | | 808 | | | | | | 808 | | |
Retained earnings (accumulated deficit)
|
| | | | 31 | | | | | | 31 | | |
Accumulated Other Comprehensive Loss
|
| | | | (488) | | | | | | (488) | | |
Total Chemours stockholders’ equity
|
| | | | 353 | | | | | | 353 | | |
Non-controlling Interests
|
| | | | 5 | | | | | | 5 | | |
Total Equity
|
| | | | 358 | | | | | | 358 | | |
Total Capitalization
|
| | | $ | 3,956 | | | | | $ | 4,456 | | |
|
| | |
Principal Amount
of Notes |
| |||
Credit Suisse Securities (USA) LLC
|
| | | $ | | | |
J.P. Morgan Securities LLC
|
| | | | | | |
Citigroup Global Markets Inc.
|
| | | | | | |
Barclays Capital Inc.
|
| | | | | | |
TD Securities (USA) LLC
|
| | | | | | |
HSBC Securities (USA) Inc.
|
| | | | | | |
RBC Capital Markets, LLC
|
| | | | | | |
Mizuho Securities USA LLC
|
| | | | | | |
Total
|
| | | $ | 500,000,000 | | |
|
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 12 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 22 | | | |
| | | | | 22 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 23 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 28 | | | |
| | | | | 29 | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 30 | | | |
| | | | | 30 | | | |
| | | | | 32 | | | |
| | | | | 32 | | | |
| | | | | 32 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| | | | | 33 | | | |
| | | | | 33 | | | |
| | | | | 33 | | | |
| | | | | 34 | | | |
| | | | | 34 | | | |
| | | | | 34 | | | |
| | | | | 37 | | | |
| | | | | 39 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 41 | | | |
| | | | | 43 | | | |
| | | | | 44 | | | |
| | | | | 56 | | | |
| | | | | 61 | | | |
| | | | | 61 | | | |
| | | | | 61 | | | |
| | | | | 63 | | | |
| | | | | 63 | | | |
| | | | | 63 | | | |
| | | | | 63 | | | |
| | | | | 64 | | | |
| | | | | 64 | | | |
| | | | | 65 | | | |
| | | | | 68 | | | |
| | | | | 69 | | | |
| | | | | 71 | | | |
| | | | | 71 | | |
| | |
Three months ended
|
| |
Year ended December 31,
|
| ||||||||||||||||||||||||||||||||||||
| | |
March 31,
2017 |
| |
March 31,
2016 |
| |
2016
|
| |
2015
|
| |
2014
|
| |
2013
|
| |
2012
|
| |||||||||||||||||||||
Ratio of Earnings to Fixed Charges
|
| | | | 4 | | | | | | 2 | | | | |
|
(a)
|
| | | |
|
(a)
|
| | | | | 185 | | | | | | 289 | | | | | | 747 | | |
Ratio of Earnings to Combined Fixed Charges and Preferred Stock Dividends
|
| | | | 4 | | | | | | 2 | | | | |
|
(a)
|
| | | |
|
(a)
|
| | | | | 185 | | | | | | 289 | | | | | | 747 | | |
|
Bond equivalent yield =
|
| |
D × N
|
| |
× 100
|
|
|
360-(D × M)
|
|
| Credit Suisse | | |
J.P. Morgan
|
| |
Citigroup
|
|
|
Barclays
|
| | | | |
TD Securities
|
|
|
HSBC
|
| |
Mizuho Securities
|
| |
RBC Capital Markets
|
|